Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest

Cancer Research

Volumn 64, Issue 13, 2004, Pages 4487-4497

  Wȩsierska Ga̧dek, Józefa ^a   Schloffer, Daniela ^a   Gueorguieva, Marieta ^a   Uhl, Maria ^a   Skladanowski, Andrzej ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; C 1305; C 1533; DACTINOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; TRIAZOLOACRIDONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL TYPE; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG POTENCY; EMBRYO; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ACRIDINES; AMSACRINE; ANIMALS; APOPTOSIS; CDC2 PROTEIN KINASE; CELL DIVISION; CYCLIN B; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; FIBROBLASTS; G2 PHASE; MICE; MICE, KNOCKOUT; POLY(ADP-RIBOSE) POLYMERASES; TRIAZOLES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042741064     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3410     Document Type: Article

References (36)

1. Berger JM. Type II DNA topoisomerases. Curr Opin Struct Biol 1998;8:26-32.
2. Austin CA, Sng JH, Patel S, Fisher JM. Novel HeLa topoisomerase II is the II beta isoforms: complete coding sequence and homology with the other type topoisomerases. Biochim Biophys Acta 1993;1172:283-91.
3. Larsen AK, Skladanowski A, Bojanowski K. The roles of topoisomerase II during the cell cycle. In: Meijer L, Guidet S, Vogel S, editors. Progress in Cell Cycle Research, Vol. 2, New York: Plenum Press; 1996. p. 229-39.
4. Cholody WM, Martelli S, Konopa J. 8-Substituted 5-[(aminoalkyl)amino]-6H- v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. Synthesis and biological activity. J Med Chem 1990;33:2852-56.
5. Kusnierczyk H, Cholody WM, Paradziej-Lukowicz J, Radzikowski C, Konopa J. Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch Immunol Ther Exp (Warsz) 1994;42:415-23.
6. Koba M, Konopa J. Interaction of antitumor triazoloacridones with DNA. Proc Am Assoc Cancer Res 2001;43:959.
7. Augustin E, Konopa J. Cell cycle and apoptosis induced by antitumor triazoloacridinones in tumor cells. Folia Histochem Cytobiol 1999;37(Suppl. 1):41.
8. Augusfin E, Plocka E, Konopa J. Induction of cell death (apoptosis) by antitumor triazoloacridinones in tumor cells. Drugs Metab Rev 2000;32 (Suppl. 1):33.
9. D'Amours D, Desnoyers S, D'Silvia I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulations of nuclear functions. Biochem J. 1999;342:249-68.
10. De Murcia G, Menissier-de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 1994;19:172-6.
11. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res 1985;101:4-15.
12. Herceg Z, Wang Z-Q. Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis. Mol Cell Biol 1999;19: 5124-33.
13. Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly(ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001;84:106-12.
14. Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochemie 1995;77:408-22.
15. Wurzer G, Herceg Z, Wesierska-Gadek J. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein. Cancer Res 2000;60: 4238-44.
16. Wang Z-Q, Auer B, Sting IL, et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 1995;9:509-20.
17. Wojciechowski J, Horky M, Gueorguieva M, Wesierska-Gadek J. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 2003;106:486-95.
18. Lövborg H, Wojciechowski J, Larsson R, Wesierska-Gadek J. Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly(ADP-ribose) polymerase-1. Cancer Res 2002;62:4206-11.
19. Wesierska-Gadek J, Schmid G. Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53 mediated G@ checkpoint. J Cell Biochem 2000;80: 85-103.
20. Tice RR, Agurell E, Anderson D, et al. Single cell gel/Comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000;35:206-21.
21. Wesierska-Gadek J, Gueorguieva M, Schloffer D, Uhl M, Wojciechowski J. Nonapoptogenic killing of HeLa cervical carcinoma cells after short exposure to the alkylating agent N-methyl-N'-Nitro-N-Nitrosoguanidine (MNNG). J Cell Biochem 2003;89:1222-34.
22. Helma C, Uhl M. A public domain image analysis program for the single cell gel electrophoresis (Comet) assay. Mutat Res 2000;466:9-15.
23. Wesierska-Gadek J, Schloffer D, Kotala V, Horky M. Escape of p53 protein from E-6 mediated degradation of HeLa cells after cisplatin therapy. Int J Cancer 2002;101: 128-36.
24. Tudzarova-Trajkovska S, Wesierska-Gadek J. Strong induction of p73 protein in vivo coincides with the onset of apoptosis in rat liver after treatment with the hepatocarcinogen N-nitrosomorpholine (NNM). J Cell Biochem 2003;90:837-55.
25. Scheltema JM, Romijn JC, Steenbrugge GJ, Beck WT, Schroder FJ, Mickisch GH. Decrease levels of topoisomerase IIα in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol 1997;123:546-54.
26. Zhou Z, Zwelling LA, Kawakami Y, et al. Adenovirus-mediated human topoisomerase IIα gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 1999;59:4618-24.
27. Chatterjee S, Cheng M-F, Berger RB, Berger SJ, Berger NA. Effect of inhibitors of poly(ADP-ribose) polymerase on the induction of grp78 and subsequent development of resistance to etoposide. Cancer Res 1995;55:868-73.
28. Godard T, Deslandes E, Sichel F, Poul J-M, Gauduchon P. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutat Res 2002;520:47-56.
29. Wesierska-Gadek J, Wang Z-Q, Schmid G. Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Cancer Res 1999;59:28-34.
30. Wesierska-Gadek J, Wojciechowski J, Schmid G. Central and carboxy-terminal regions of human p53 protein are essential for interaction and complex formation with PARP-1. J Cell Biochem 2003;89:220-32.
31. Wesierska-Gadek J, Wojciechowski J, Schmid G. Phosphorylation regulates the interaction and complex formation between wt p53 protein and PARP-1. J Cell Biochem 2003;89:1260-84.
32. Blair-Zajdel ME, Blair GE. The intracellular distribution of the transformation-associated protein p53 in adenovirus-transformed rodent cells. Oncogene 1988;2: 579-84.
33. Waf/Cip1 pathway. Oncogene 2001;20:3173-84.
34. Kanai M, Tong W-M, Sugihara E, Wang Z-Q, Fukasawa K, Miwa M. Involvement of poly(ADP-ribose) polymerase-1 and poly(ADP-ribosyl)ation in regulation of centrosome function. Mol Cell Biol 2003;23:2451-62.
35. Saxena A, Saffery R, Wong LH, Kalitsis P, Choo KHA. Centromere proteins Cenpa, Cenpb, and Bub3 interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosylated). J Biol Chem 2002;277:26921-26.
36. Malanga M, Althaus FR. Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing. J Biol Chem 2004;279:5244-8.